Table 2.

Treatment Utilization Rates for Hepatocellular Carcinoma

Author, Year	Study Years	Number of HCC Patients	Rates of any HCC Treatment (%)
Altekruse 20129	1998 – 2008	21390	NR
Cance 200010	1985 – 1996	6353	3213 (50.6%)
Harrison 200411	1997 – 2003	264	190 (72.0%)
Jan 201212	2003 – 2011	206	145 (70.4%)
Jou 201013	2002 – 2008	319	207 (64.9%)
Kanwal 201232	2001 – 2007	267	NR
Kemmer 200814	2000 – 2005	169	NR
Kitisin 201115	2000 – 2009	1010	841 (83.3%)
Kooby 200816	1990 – 2004	501	307 (61.3%)
Kozyreva 201117	1998 – 2008	335	245 (73.1%)
Leykum 200718	2000 – 2005	72	20 (27.8%)
Sanyal 201019	2002 – 2008	4406	3757 (85.3%)
Sarkar 201220	1997 – 2008	31*	NR
Schwartz 199521	1998 – 1994	115	NR
Shah 201122	1991 – 2005	8730	2595 (29.7%)
Stravitz 200823	1997 – 2005	297	233 (78.5%)
Stuart 199624	1986 – 1995	314	233 (74.2%)
Theodoropoulos 201125	2001 – 2007	81	63 (77.8%)
Tong 201026	2000 – 2007	278	236 (84.9%)
Wong 201227	1992 – 2009	618	427 (69.1%)
Yang 201128	2007 – 2009	453	271 (55.2%)
Yu 201029	2002 – 2008	462	NR
Zak 201130	1996 – 2006	12148	NR
Zaydfudim 201031	2004 – 2006	680	NR

NR-Not Reported

^*Subset of total population with cirrhosis